{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:18:18Z","timestamp":1778635098269,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21907014"],"award-info":[{"award-number":["21907014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773063"],"award-info":[{"award-number":["81773063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81961138017"],"award-info":[{"award-number":["81961138017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.drudis.2020.12.010","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T12:22:35Z","timestamp":1609244555000},"page":"631-636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions"],"prefix":"10.1016","volume":"26","author":[{"given":"Min","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Zhang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-5545","authenticated-orcid":false,"given":"Lee","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.12.010_bib0005","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2020.12.010_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2020.12.010_bib0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2020.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ajem.2020.03.011","article-title":"Sex-based pharmacotherapy in acute care setting, a narrative review for emergency providers","volume":"38","author":"Mehta","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drudis.2020.12.010_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2020.12.010_bib0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2020.12.010_bib0035","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2020.12.010_bib0040","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drudis.2020.12.010_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2020.12.010_bib0050","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2020.12.010_bib0055","article-title":"An exploratory randomized, controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI)","author":"Li","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.drudis.2020.12.010_bib0060","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"384","key":"10.1016\/j.drudis.2020.12.010_bib0065","first-page":"30085","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"4","key":"10.1016\/j.drudis.2020.12.010_bib0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00542151","article-title":"The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects","volume":"26","author":"Frisk-Holmberg","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.drudis.2020.12.010_bib0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.drudis.2020.12.010_bib0080","series-title":"WHO Discontinues Hydroxychloroquine and Lopinavir\/Ritonavir Treatment Arms for COVID-19","author":"WHO","year":"2020"},{"issue":"1","key":"10.1016\/j.drudis.2020.12.010_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"issue":"10","key":"10.1016\/j.drudis.2020.12.010_bib0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/js990108g","article-title":"Physicochemistry, pharmacokinetics, and pharmacodynamics of S\u2010nitrosocaptopril crystals, a new nitric oxide donor","volume":"88","author":"Jia","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"1-2","key":"10.1016\/j.drudis.2020.12.010_bib0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(99)00794-3","article-title":"Antiangiogenic effects of S-nitrosocaptopril crystals as a nitric oxide donor","volume":"391","author":"Jia","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.drudis.2020.12.010_bib0100","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0278-6915(01)00079-5","article-title":"Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities","volume":"39","author":"Jia","year":"2001","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.drudis.2020.12.010_bib0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2018.09.020","article-title":"A novel S-nitrosocaptopril monohydrate for pulmonary arterial hypertension: H2O and \u2013SNO intermolecular stabilization chemistry","volume":"129","author":"Zhou","year":"2018","journal-title":"Free Radical Biol. Med."},{"issue":"6","key":"10.1016\/j.drudis.2020.12.010_bib0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJM199302113280605","article-title":"Inhaled nitric oxide for the adult respiratory distress syndrome","volume":"328","author":"Rossaint","year":"1993","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.drudis.2020.12.010_bib0115","unstructured":"ClinicalTrials.gov. Efficacy of captopril in Covid-19 patients with severe acute respiratory syndrome (SARS) CoV-2 pneumonia (CAPTOCOVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355429 [Accessed December 15, 2020]."},{"issue":"5","key":"10.1016\/j.drudis.2020.12.010_bib0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-0369-9","article-title":"Reply to:\u2019 Interaction between RAAS inhibitors and ACE2 in the context of COVID-19\u2019","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"8","key":"10.1016\/j.drudis.2020.12.010_bib0125","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.drudis.2020.12.010_bib0130","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.drudis.2020.12.010_bib0135","series-title":"FDA\u2019s Actions in Response to 2019 Novel Coronavirus at Home and Abroad","author":"FDA","year":"2020"},{"key":"10.1016\/j.drudis.2020.12.010_bib0140","unstructured":"Stone, A. Regulatory issues in microbicide development 2010 [cited 2020 December 31]. Available from: https:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/9789241599436\/en\/."},{"key":"10.1016\/j.drudis.2020.12.010_bib0145","unstructured":"Ministry of Science and Technology, China 2020. http:\/\/most.gov.cn\/xinwzx\/xwzx\/twzb\/fbh20021501\/twbbwzsl\/202002\/t20200216_151615.htm [Accessed December 15, 2020]."},{"issue":"1","key":"10.1016\/j.drudis.2020.12.010_bib0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine\u2010based antitubercular drug","volume":"144","author":"Jia","year":"2005","journal-title":"Br. J. Pharmacol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620305286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620305286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:48:57Z","timestamp":1761223737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620305286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1359644620305286"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.12.010","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}